Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RecruitingPhase 4
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress - The ASPIRE-AF Trial
Who can join
Ages 55 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. have ≥1 episode of clinically important AFOTS during any of the following conditions: 1. noncardiac surgery in the past 35 days, with at least an overnight hospital admission aftersurgery; 2. noncardiac day surgery resulting in a large enough physiological insult to be able to cause AFOTS, as judged by the local investigator; or 3. acute medical illness requiring hospital admission in the past 35 days and resulting in a large enough physiological insult to be able to cause AFOTS, as judged by the local investigator; 2. sinus rhythm at the time of randomization; 3. any of the following high-risk criteria: 1. age 55-64 years, and having either known cardiovascular disease, recent major vascular surgery, a CHA2DS2VASc score ≥3, or an elevated postoperative troponin level; 2. age 65-74 years, and having either known cardiovascular disease, recent major vascular surgery, a CHA2DS2VASc score ≥2, or an elevated postoperative troponin level; OR 3. age ≥75 years.; 4. provide written informed consent Exclusion Criteria: 1. any cardiac diagnosis as the primary reason for hospital admission; 2. history of documented chronic AF prior to noncardiac surgery; 3. need for long-term systemic anticoagulation; 4. ongoing need for long-term dual antiplatelet treatment; 5. contraindication to oral anticoagulation; 6. severe renal insufficiency (CrCl \<20 ml/min); 7. severe liver cirrhosis (i.e., Child-Pugh Class C) 8. acute stroke in the past 14 days; 9. underwent cardiac surgery in the past 35 days; 10. history of nontraumatic intracranial, intraocular, or spinal bleeding; 11. hemorrhagic disorder or bleeding diathesis; 12. expected to be non-compliant with follow-up and/or study medications; 13. known life expectancy less than 1 year due to concomitant disease; 14. women who are pregnant, breastfeeding, or of childbearing potential who are not taking effective contraception; OR 15. previously enrolled in the trial
About the study
Multinational, investigator-initiated study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient atrial fibrillation occurring transiently with stress and additional stroke risk factors.
What is being tested
- Non-vitamin K oral anticoagulant (NOAC) (drug)
Sponsor: Population Health Research Institute · Participants: 2,270 · Started: Jun 14, 2019
Contact the study team
- Cassie McDonald · Phone: 1-905-594-0560
Official record on ClinicalTrials.gov — NCT03968393
Locations in the U.S.
| California | Cedars-Sinai Medical Center, Los Angeles |
| Texas | Mcgovern Medical School at University of Texas, Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.